| Literature DB >> 26200956 |
Ralciane de Paula Menezes1, Joseane Cristina Ferreira2, Walkiria Machado de Sá3, Tomaz de Aquino Moreira3, Lucivânia Duarte Silva Malvino3, Lucio Borges de Araujo4, Denise Von Dolinger de Brito Röder1, Mario Paulo Amante Penatti5, Regina Celia Candido2, Reginaldo Dos Santos Pedroso1.
Abstract
Infections by Candida species are a high-impact problem in public health due to their wide incidence in hospitalized patients. The goal of this study was to evaluate frequency, susceptibility to antifungals, and genetic polymorphism of Candida species isolated from clinical specimens of hospitalized patients. The Candida isolates included in this study were obtained from blood cultures, abdominal fluids, and central venous catheters (CVC) of hospitalized patients at the Clinical Hospital of the Federal University of Uberlândia during the period of July 2010 - June 2011. Susceptibility tests were conducted by the broth microdilution method. The RAPD-PCR tests used employed initiator oligonucleotides OPA09, OPB11, and OPE06. Of the 63 Candida isolates, 18 (28.5%) were C. albicans, 20 (31.7%) were C. parapsilosis complex species, 14 (22.2%) C. tropicalis, four (6.4%) C. glabrata, four (6.4%) C. krusei, two (3.3%) C. kefyr, and one (1.6%) C. lusitaniae. In vitro resistance to amphotericin B was observed in 12.7% of isolates. In vitro resistance to azoles was not detected, except for C. krusei. The two primers, OPA09 and OPB11, were able to distinguish different species. Isolates of C. albicans and C. parapsilosis complex species presented six and five clusters, respectively, with the OPA09 marker by RAPD-PCR, showing the genetic variability of the isolates of those species. It was concluded that members of the C. parapsilosis complex were the most frequent species found, and most isolates were susceptible to the antifungals amphotericin B, flucozanole, and itraconazole. High genetic polymorphisms were observed for isolates of C. albicans and C. parapsilosis complex species, mainly with the OPA09 marker.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26200956 PMCID: PMC4544240 DOI: 10.1590/S0036-46652015000300001
Source DB: PubMed Journal: Rev Inst Med Trop Sao Paulo ISSN: 0036-4665 Impact factor: 1.846
Fig. 1Distribution of Candida spp. according to age of hospitalized patients who developed systemic candidiasis during the period of July 2010-June 2011.
Frequency of Candida species isolated from clinical specimens of patients from the Clinical Hospital of Federal University of Uberlândia who developed systemic candidiasis during the period of July 2010-June 2011
| Clinical specimens |
|
|
| Others | Total |
|---|---|---|---|---|---|
| Blood | 11 (17.4%) | 9 (14.3%) | 10 (15.9%) | 5 (7.9%) | 35 (55.6%) |
| CVC | 6 (9.5%) | 1 (1.6%) | 1 (1.6%) | 1 (1.6%) | 9 (14.3%) |
| Blood + CVC | 3 (4.8%) | 5 (7.9%) | 2 (3.2%) | 2 (3.2%) | 12 (19.0%) |
| Abdominal fluids | 0 (0.0%) | 3 (4.8%) | 1 (1.6%) | 3 (4.8%) | 7 (11.1%) |
|
|
|
|
|
|
|
Other species: C. krusei (4); C. glabrata(4); C. lusitaniae (1); and C. kefyr (2). CVC = central venous catheter.
In-vitro susceptibility of Candida species to three antifungal agents
| Species (n) | Antifungal agents | MIC (μg/mL) | Resistant n (%) | ||
|---|---|---|---|---|---|
| Range | MIC 50 | MIC90 | |||
|
| Amphotericin B | 0.5-2.0 | 1.0 | 1.0 | 1 (5%) |
| Fluconazole | 0.125-1.0 | 0.5 | 0.5 | 0 | |
| Itraconazole | 0.03-0.125 | 0.03 | 0.03 | 0 | |
|
| Amphotericin B | 0.5-2.0 | 0.5 | 1.0 | 1 (5.6%) |
| Fluconazole | 0.125-0.5 | 0.125 | 0.5 | 0 | |
| Itraconazole | 0.03 | 0.03 | 0.03 | 0 | |
|
| Amphotericin B | 0.5-1.0 | 1.0 | 1.0 | 0 |
| Fluconazole | 0.125-0.5 | 0.25 | 0.5 | 0 | |
| Itraconazole | 0.03-0.06 | 0.03 | 0.06 | 0 | |
|
| Amphotericin B | 1.0-2.0 | - | - | 3 (75%) |
| Fluconazole | - | - | - | 4 (100%) | |
| Itraconazole | 0.03-0.12 | - | - | 0 | |
|
| Amphotericin B | 1.0-2.0 | - | - | 2 (50%) |
| Fluconazole | 0.5-4.0 | - | - | 0 | |
| Itraconazole | 0.25-0.3 | - | - | 0 | |
|
| Amphotericin B | 0.5-2.0 | - | - | 1 (50%) |
| Fluconazole | 0.125-0.5 | - | - | 0 | |
| Itraconazole | 0.06-0.125 | - | - | 0 | |
|
| Amphotericin B | 1 | - | - | 0 |
| Fluconazole | 0.25 | - | - | 0 | |
| Itraconazole | 0.03 | - | - | 0 | |
C. krusei is intrinsically resistant to fluconazole.
Frequency of cluster profiles and isolates per cluster with primers OPA09 and OPB11
| Species(n) | OPA09 | OPB11 | ||
|---|---|---|---|---|
| Molecular profile | Frequency of isolates | Molecular profile | Frequency of isolates | |
|
| A | 10 | A | 13 |
| B | 3 | B | 4 | |
| C | 3 | C | 1 | |
| D | 3 | D | 1 | |
| E | 1 | |||
|
| A | 7 | A | 14 |
| B | 4 | B | 4 | |
| C | 4 | |||
| D | 1 | |||
| E | 1 | |||
| F | 1 | |||
|
| A | 14 | A | 13 |
| B | 1 | |||
A cluster was considered when it grouped isolates with 100% similarity.